Overview

Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder

Status:
Completed

Trial end date:
2008-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether atomoxetine is effective in reducing ADHD (Attention Deficit/Hyperactivity Disorder) symptoms in children and adolescents with ASD (Autism Spectrum Disorder).

Phase:

Phase 4

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Atomoxetine Hydrochloride